Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.40 |
| ▸ | ALPL | P05186 | 2/20 | 0.40 |
| ▸ | XIAP | P98170 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.35 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14632793 | 0.83 | TSHR (0.50) | ALDH1A1ENPP3ALPLXIAPTSHR | |
| SCHEMBL667656 | 0.82 | KDM4E (0.40) | FAAHNR1H2HSP90AA1HSP90AB1KMT2A | |
| SCHEMBL25249092 | 0.82 | HSP90AA1 (0.43) | FAAHNR1H2HSP90AA1HSP90AB1MEN1 | |
| SCHEMBL23500483 | 0.82 | FAAH (0.38) | ALDH1A1FAAHNR1H2HSP90AA1HSP90AB1 | |
| SCHEMBL23500384 | 0.80 | FAAH (0.39) | FAAHNR1H2HSP90AA1HSP90AB1L3MBTL1 | |
| SCHEMBL4038261 | 0.78 | NR1H2 (0.36) | ALDH1A1FAAHNR1H2HSP90AA1HSP90AB1 | |
| SCHEMBL8023407 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TSHRCYP1A2MAPK1MEN1 | |
| SCHEMBL1852996 | 0.78 | KLK3 (0.44) | ALDH1A1TSHRHSP90AA1HSP90AB1CYP2C19 | |
| SCHEMBL359804 | 0.78 | FAAH (0.37) | ALDH1A1ENPP3ALPLXIAPFAAH | |
| SCHEMBL1001764 | 0.77 | FAAH (0.35) | ALDH1A1FAAHNR1H2HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116134022-B | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024131937-A1 | COMPOUND SERVING AS EIF4E INHIBITOR AND USE THEREOF | 南京圣和药业股份有限公司 | 2024-06-27 | — | — | WO | disclosed |
| CN-117684188-A | Electrochemical synthesis method of 5-aminopyrazole thioether compound | 阜阳师范大学 | 2024-03-12 | — | — | CN | disclosed |
| CN-115074760-B | Electrochemical synthesis method of 5-aminopyrazole-4-thiocyanate compound | 阜阳师范大学 | 2023-11-03 | — | — | CN | disclosed |
| US-20230339927-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339927-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023131234-A1 | CRYSTALLINE FORMS OF AN ATR INHIBITOR | SHANGHAI ANTENGENE CORPORATION LIMITED (CN) | 2023-07-13 | — | — | WO | disclosed |
| CN-116134022-A | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4175948-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-05-10 | — | — | EP | disclosed |
| CN-115074760-A | Electrochemical synthesis method of 5-aminopyrazole-4-thiocyanic acid ester compound | 阜阳师范大学 | 2022-09-20 | — | — | CN | disclosed |
| EP-2663553-B1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORP (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2885291-A1 | VEGFR3 INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014109414-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | 富士フイルム株式会社 (JP) | 2014-07-17 | — | — | WO | disclosed |
| US-20140073620-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-13 | — | — | US | disclosed |
| WO-2014026243-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014026243-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-02-20 | — | — | WO | disclosed |
| EP-2663553-A2 | QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2012030944-A2 | QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20080269266-A1 | NOVEL COMPOUNDS 747 | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339927-A1 | ATR INHIBITORS AND USES THEREOF | ATR, CHEK1, CHEK2 | ALDH1A1 4462/4885ENPP3 1824/4885ALPL 3632/4885 |
| US-20080269266-A1 | NOVEL COMPOUNDS 747 | UGT2B7, UGT1A7, CYP3A7 | ALDH1A1 790/4885ENPP3 1770/4885ALPL 3951/4885 |
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | JAK3, JAK2, JAK1 | ALDH1A1 4518/4885ENPP3 2413/4885ALPL 4656/4885 |
| US-20140073620-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | ALDH1A1 2289/4885ENPP3 441/4885ALPL 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.